Perthera Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$4.47M
- Investors
-
1
Perthera General Information
Description
Developer of a therapeutic intelligence platform designed to focus on extending cancer patients' lives through advancing precision medicine and computational engines. The company's platform offers patients precisely matched therapeutic options ranked for the highest probability of the best outcome with its therapeutic recommendations, enabling physicians to treat their patients with medications that target the specific biomarkers associated with their patient's unique cancer.
Contact Information
Website
www.perthera.comCorporate Office
- 8200 Greensboro Drive
- Suite 900
- McLean, VA 22102
- United States
Corporate Office
- 8200 Greensboro Drive
- Suite 900
- McLean, VA 22102
- United States
Perthera Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A2) | 30-Sep-2022 | $4.47M | Completed | Generating Revenue | ||
| 5. Debt - PPP | 12-Apr-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 07-Jan-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 03-Jan-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 06-Jul-2016 | $9.2M | $10.4M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 11-Aug-2015 | $1.27M | $1.27M | Completed | Startup |
Perthera Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A1 | 2,178,034 | $0.001000 | $1.81 | $1.81 | 1x | $1.81 | 3.35% | |
| Series A | 5,468,585 | $0.001000 | $1.81 | $1.81 | 1x | $1.81 | 8.41% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Perthera Comparisons
Industry
Financing
Details
Perthera Competitors (22)
One of Perthera’s 22 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| CureMatch | Venture Capital-Backed | San Diego, CA | ||||
| IFM Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA |
Perthera Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Perthera Patents
Perthera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240404705-A1 | Methods for predicting relative benefit of therapy options and devices thereof | Pending | 31-May-2023 | ||
| US-11574718-B2 | Outcome driven persona-typing for precision oncology | Active | 31-May-2018 | ||
| US-20190371443-A1 | Outcome driven persona-typing for precision oncology | Active | 31-May-2018 | ||
| US-11475995-B2 | Integration of multi-omic data into a single scoring model for input into a treatment recommendation ranking | Active | 07-May-2018 | ||
| US-20190385740-A1 | Integration of multi-omic data into a single scoring model for input into a treatment recommendation ranking | Active | 07-May-2018 | G16H20/10 |
Perthera Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Perthera Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Pilot Growth Equity | Growth/Expansion | Minority |
Perthera Acquisitions (1)
Perthera’s most recent deal was a Merger/Acquisition with Oxygen Healthcare. The deal was made on 02-Jun-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oxygen Healthcare | 02-Jun-2022 | Merger/Acquisition | Other Healthcare Technology Systems |
Perthera FAQs
-
When was Perthera founded?
Perthera was founded in 2012.
-
Where is Perthera headquartered?
Perthera is headquartered in McLean, VA.
-
What is the size of Perthera?
Perthera has 27 total employees.
-
What industry is Perthera in?
Perthera’s primary industry is Other Healthcare Technology Systems.
-
Is Perthera a private or public company?
Perthera is a Private company.
-
What is the current valuation of Perthera?
The current valuation of Perthera is .
-
What is Perthera’s current revenue?
The current revenue for Perthera is .
-
How much funding has Perthera raised over time?
Perthera has raised $26.8M.
-
Who are Perthera’s investors?
Pilot Growth Equity has invested in Perthera.
-
Who are Perthera’s competitors?
Allogene Therapeutics, CureMatch, IFM Therapeutics, Iovance Biotherapeutics, and Intellia Therapeutics are some of the 22 competitors of Perthera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
